Post by Olivia Theisen-Lauk

We are proud to share this important milestone: the publication of our multi-center (7 institutions) collaboration, representing one of the largest collections assembled on this rare disease. Pulmonary Artery Sarcoma Study: A Multi-center ESTS Working Group Evaluating Diagnosis, Treatment, and Outcomes Thoracic Oncology | Original Article This achievement reflects years of dedicated work and close collaboration across institutions. Key findings: 🔎 Diagnosis challenges • Misdiagnosed as pulmonary embolism in 49% • Diagnostic delay: 3–9 months • Dyspnea (81%) and chest pain (50%) dominate 📊 Disease characteristics • Bilateral involvement: 58% • Metastatic at diagnosis: 30–50% • Intimal sarcoma: 83% ⚙️ Treatment • Surgery cornerstone (endarterectomy ~60%) • Multimodal: chemo (60%) + radiotherapy (53%) 📈 Key outcome • OS (75th percentile): 34 vs 11 months (multimodal vs surgery only) • Survival benefit with multimodal (p=0.022) • No PFS difference: 19 vs 16 months 💡 Takeaway Multimodal therapy improves survival—but prognosis remains poor. Earlier diagnosis & centralized care are critical. 👥 Authors Olivia Lauk, Bianca Battilana, Ulrike Held, Claudia Lourenço Rodrigues, Martina Haberecker, Kathrin Chiffi, Tom Verbelen, Marc de Perrot, Bedrettin Yildizeli, Michael Lanuti, Bernhard Moser, Stefan Schwarz, Hussein Nasser Awada, Rene Horsleben Petersen, Isabelle Schmitt-Opitz #ESTS #ThoracicSurgery #Sarcoma #Oncology #RareDiseases #MultimodalTreatment